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Chondroprotection by urocortin 
involves blockade of the 
mechanosensitive ion channel 
Piezo1
K. M. Lawrence1, R. C. Jones1, T. R. Jackson1, R. L. Baylie2, B. Abbott  1, B. Bruhn-Olszewska1, 
T. N. Board3, I. C. Locke4, S. M. Richardson  5 & P. A. Townsend1
Osteoarthritis (OA) is characterised by progressive destruction of articular cartilage and chondrocyte 
cell death. Here, we show the expression of the endogenous peptide urocortin1 (Ucn1) and two receptor 
subtypes, CRF-R1 and CRF-R2, in primary human articular chondrocytes (AC) and demonstrate its 
role as an autocrine/paracrine pro-survival factor. This effect could only be removed using the CRF-R1 
selective antagonist CP-154526, suggesting Ucn1 acts through CRF-R1 when promoting chondrocyte 
survival. This cell death was characterised by an increase in p53 expression, and cleavage of caspase 9 
and 3. Antagonism of CRF-R1 with CP-154526 caused an accumulation of intracellular calcium (Ca2+) 
over time and cell death. These effects could be prevented with the non-selective cation channel blocker 
Gadolinium (Gd3+). Therefore, opening of a non-selective cation channel causes cell death and Ucn1 
maintains this channel in a closed conformation. This channel was identified to be the mechanosensitive 
channel Piezo1. We go on to determine that this channel inhibition by Ucn1 is mediated initially by an 
increase in cyclic adenosine monophosphate (cAMP) and a subsequent inactivation of phospholipase A2 
(PLA2), whose metabolites are known to modulate ion channels. Knowledge of these novel pathways 
may present opportunities for interventions that could abrogate the progression of OA.
Articular cartilage is the dense connective tissue that lines the surfaces of diarthrodial joints providing a 
low-friction surface for joint loading and articulation. The extracellular matrix of articular cartilage comprises 
primarily of proteoglycans and type II collagen, which are maintained by a sparse population of chondrocytes1. 
Osteoarthritis (OA) is characterised by progressive destruction and loss of cartilage, which is attributed to a reduc-
tion in the number of viable chondrocytes in articular cartilage2 and the severity of cartilage damage has been 
shown to correlate negatively with the number of remaining chondrocytes3. Chondrocyte cell death is essentially 
apoptotic in nature4, with a close correlation between p53 expression and death5. Currently, the only treatments 
for OA are steroidal and non-steroidal anti-inflammatory drugs, or in severe cases total joint replacement sur-
gery6. However, these strategies only ameliorate symptoms and do not address the underlying pathology, namely 
chondrocyte death. The prevention of this death and/or the protection of remaining cells from further destruction 
would represent a treatment strategy that addresses important cartilage degrading diseases such as OA at a more 
fundamental level. Despite the fact that chondrocyte cell death is now well established as a contributing factor 
in the loss of articular cartilage integrity, the cause of this death is currently unclear. However, several molecular 
factors have been implicated, including nitric oxide (NO), which has been shown to induce death in vitro and in 
vivo7, 8. Furthermore, NO is abundant in OA joints in vivo and is thought to be elevated by mechanical stress9.
We have recently demonstrated the expression in the human chondrocyte cell line C-20/A4 of the 
corticotropin-releasing factor (CRF)-related peptide urocortin 1 (Ucn1). Furthermore, we demonstrated that 
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the addition of exogenously applied Ucn1 to C-20/A4 cells was able to protect against NO-induced apoptosis. 
Intriguingly, we also discovered that Ucn1 works as an essential endogenous autocrine pro-survival molecule in 
the absence of apoptotic stimuli, since its removal from the surrounding milieu in cultured cells caused cell death10. 
Significantly, Ucn1 has recently been found to be upregulated in the synovial fluid of patients with rheumatoid 
arthritis and has been shown to reduce inflammation in mouse models of the disease11–13.
Ucn1 is a 40 amino acid long peptide and was cloned based on sequence homology to CRF, the parent molecule14. 
These peptides are evolutionary ancient molecules having representatives in lower vertebrates such as sauvag-
ine and urotensin, found in amphibia and fish respectively15, 16. Although originally found in the brain, Ucn1 
has now been found in many peripheral tissues where it exerts diverse effects including: cardioprotection17, 
antiresorptive activity in bone18 and control of the myometrium at term19. Two further paralogues of Ucn1 
have also been isolated; Ucn2 (Human Stresscopin Related Peptide), and Ucn3 (Human Stresscopin), which are 
composed of 38 and 39 amino acids respectively20. All ligands transduce signals by binding to two different G 
protein-linked receptor subtypes CRF R1 and CRF-R2. Furthermore, ligand binding studies have revealed that 
CRF and Ucn1 have affinity for both receptor subtypes, whereas Ucn2 and Ucn3 bind exclusively to CRF-R221. 
This system is completed by corticortropin releasing factor-binding protein (CRF-BP), which acts as a decoy 
receptor for both CRF and Ucn122, 23, implying that this family of receptors and ligands may be self-regulating.
There is a growing body of evidence implicating Ucn1 in ion channel modulation in different cell types and 
under different physiological conditions24. Ucn1 can affect a whole range of ion channel species in different tissues 
resulting in profound physiological effects. For example in the vasculature, Ucn1 has been demonstrated to relax 
the endometrial smooth muscle by activation of large Ca2+-activated K+ channels (BK channels)25. Whereas the 
cardioprotective effect of Ucn1 involves a diverse range of ion channels including the inhibition of L-type calcium 
channels26 but also to increase KATP channel gene expression and activation17, 27. Furthermore, in the male repro-
ductive system, the reported regulation of spermatogenesis by Ucn1 has been demonstrated to involve T-type 
Ca2+ channels28, whereas the osteoclast inhibitory effect of Ucn1 involves regulation of Ca2+ ions by inhibition of 
a TRPC1-like cation current18.
The presence of ion channels on chondrocytes, the so called chondrocyte “channelome” is of growing inter-
est within the field of OA29. A number of ion channels have been shown to be expressed on the surface of the 
chondrocytes, which contribute to the metabolic activity of the cell. This activity is essential for induction and 
production of the ECM proteins in response to mechanical damage and stress30. The importance of calcium influx 
through these channels has also been described, in particular in response to mechanical impact. Gene knockout 
of a T-type calcium channel expressed on both osteoblasts and chondrocytes in a mouse model was shown to 
reduce OA histology scores31. Furthermore, membrane ion channel characteristics and expression have been 
shown to change with development of OA32, 33 and specifically the acid sensing potassium channel (TASK-2), 
epithelial sodium channel (ENaC) and Ca2+ activated chloride channel (anoctamin-1, TMEM16) have all been 
shown to be decreased in OA patients compared to healthy individuals. Conversely Ca2+ activated potassium 
channels (KCa3.1, “SK” and KCa1.1, “BK”) and aquaporin 1 (AQP1) were shown to be strongly up-regulated32, 33. 
Recently, the newly discovered, Piezo1 and Piezo2 ion channels, have been found in cartilage and are thought 
to represent important chondrocyte mechanotransduction pathways. These ion channels are large mechanically 
activated Ca2+-permeable cation channels and are both abundant in organs with mechanical functions including 
chondrocytes34–38.
The aim of our study was to elucidate the pathway by which Ucn1 protects chondrocytes. To this end we used 
the C-20/A4 cell line to first identify the biological mechanisms of Ucn1 protection before confirming key exper-
iments in primary human articular chondrocytes (AC). The C-20/A4 phenotype and gene expression profiling in 
both monolayer and 3D alginate culture systems, confirmed their suitability as an appropriate cell line to use in 
the study of chondrocyte biology39. Furthermore, C-20/A4 cells display the polygonal cobblestone morphology 
and the differentiated phenotype typical of human chondrocytes such as the expression of various cartilage spe-
cific molecules including collagen type II, IX and XI40.
We report here that the Ucn1 system (Ucn1, CRF-R1 and CRF-R2) is expressed in AC and to confirm that 
Ucn1 is essential for the survival of AC cells in the absence of pro-apoptotic stimuli. Furthermore, we have elu-
cidated the downstream signalling pathway by which Ucn1 exerts this protective effect and the end effector ion 
channel subtype as Piezo1. These findings provide extremely important and novel insights into the development 
of treatments for OA. These treatments rather than being simply palliative will address the fundamental problem 
of maintaining chondrocyte survival. Therefore, pharmaceuticals derived from this work could be potentially 
prophylactic as well as halting the progression of the extant disease.
Results
The Urocortin system is present in primary human AC. Having previously established that compo-
nents of the Ucn1 signalling axis (Ucn1, CRF-R1 and CRF-R2) are expressed in the human chondrocyte cell line 
C-20/A410 we sought here to examine the presence and validate this system in AC using RT-PCR. Analysis con-
firmed that Ucn1 itself and both the CRF-R1 and CRF-R2 receptors were expressed in AC (Fig. 1).
The pro-survival effect of Ucn1 in both C-20/A4 and AC is mediated through the CRF-1 recep-
tor. We have previously demonstrated that Ucn1 protects the C-20/A4 cell line from NO-induced cell death 
and is essential for cell survival in the absence of exogenously applied pro-apoptotic stimuli10.
Using specific antagonists against CRF-R1 (CP-154526) and CRF-R2 (astressin 2B) receptors we demonstrate 
a dose dependant increase in cell death after 8 h. C-20/A4 cells exhibited a rounded rather than a flattened mor-
phology and became increasingly dislodged from the culture dish. Cell death was confirmed using Annexin V/
PI staining with flow cytometry (Fig. 2A,B). A similar level of cell death was observed when cells were exposed 
to both CP-154526 and astressin 2B in combination, suggesting that the effect is not cumulative and that CRF-R1 
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is the sole receptor responsible for the demonstrated effects. Having established the CRF-R1 receptor as being 
responsible for Ucn1 mediated protection in C-20/A4 cells, we investigated the effect of Ucn1 blockade on AC 
and found Ucn1 also acts as a pro-survival molecule in AC through CRF-R1 (Fig. 2A,C).
CRF-R1 blockade upregulates p53 and activates the intrinsic apoptotic pathway. To determine 
the mechanism of cell death caused by the addition of the CRF-R1 antagonist, we assessed the levels of p53, and 
cleaved-caspases 3, 8 and 9 in C-20/A4 cells by western blotting. When the cells were treated with CP-154526, p53 
expression was up regulated and cleavage products for both caspases 9 and 3 were detected; cleaved-caspase 8, 
however, was not detected (data not shown). No effects were seen with the CRF-R2 selective antagonist astressin 
2B (Fig. 3). Thus, our data suggests that CP-154526 induced cell death is working through the intrinsic apoptotic 
pathway and is associated with p53 upregulation.
CP-154526 treatment causes an increase in intracellular Ca2+ levels which lead to chondrocyte 
cell death. Using fluorescence microscopy we found a large increase in intracellular Ca2+ levels produced 
by the CRF-R1 antagonist from 0.5 hours to a maximum at 3 hours of incubation in C-20/A4 cells. This high 
level of Ca2+ influx was prevented with a co-treatment of the non-selective cation channel blocker Gadolinium 
(Gd3+) (Fig. 4A,B). Furthermore Gd3+ treatment was able to protect C-20/A4 cells from CP-154526 induced cell 
death (Fig. 4C). These experiments were repeated using AC where CP-154526 again caused an increase in intra-
cellular Ca2+ which could be inhibited by Gd3+ treatment (Fig. 4D,E). Gd3+ was also able to protect AC against 
CP-154526-induced cell death.
Ucn1 exerts its chondroprotective effect by maintaining Piezo1 in a closed conforma-
tion. Using a panel of siRNA constructs we demonstrated that only silencing of the Piezo channels caused pro-
tection from cell death induced by CP-154526 as measured both by Annexin V/PI staining and LDH release. This 
effect was more pronounced for Piezo1 than Piezo2 (Supplementary Figure S1). From this initial study, we gained 
an insight into the nature of the channel involved in antagonist induced cell death. Next we repeated these initial 
experiments using siRNA to Piezo1 and Piezo2 and found that only when Piezo1 was lost did we see significant 
protection from CP-154526-induced cell death (Fig. 5A–C). We subsequently determined by silencing Piezo1 and 
Piezo2, that Piezo1 is responsible for CP-154526-induced Ca2+ influx and overload (Fig. 5D,E).
Ucn1 binding to CRF-R1 promotes cell survival via cAMP activation and inhibition of PLA2 activ-
ity. Due to the promiscuity of CRF receptor coupling to different G proteins, we determined whether the cou-
pling in our system was to the Gαs or Gαq subunits. We, therefore, investigated the possibility that C-20/A4 cells 
could be rescued from CP 154526 induced cell death by activating these pathways. The adenylate cyclase activator 
forskolin and the phospholipase C (PLC) activator m-3M3FBS were used to activate cAMP and PLC signalling, 
respectively, in the presence of CP-154526, thereby bypassing receptor activation by Ucn1. When this was per-
formed we found that forskolin but not m-3M3FBS was able to rescue cells from CP-154526 induced cell death. 
Thus, in C-20/A4 cells Ucn1 binds to CRF-R1 and subsequently signals through adenylate cyclase activation and 
the generation of cAMP is required to maintain cell survival (Fig. 6A).
The phospholipase A2 (PLA2) enzyme and its metabolites can modulate numerous ion channel species, we 
therefore investigated the role of PLA2 in antagonist-induced cell death. When cells were treated with CP-154526 
and the PLA2 inhibitor, OBAA, we found that inhibition of PLA2 activity rescued C-20/A4 cells from CP-154526 
induced cell death. This suggested that lipid modulator production by PLA2 may have a role in antagonist induced 
cell death by causing a non-selective cation channel to become opened in the absence of Ucn1 (Fig. 6B).
Discussion
This is the first study to demonstrate the presence of the Ucn1 system in AC (Fig. 1) and to demonstrate that 
endogenously released Ucn1 is essential for their maintenance and survival in the absence of externally applied 
noxious stimuli. Our data implies an essential pro-survival paracrine/autocrine role for Ucn1 in human chon-
drocytes (Fig. 2). Previously, we reported that abrogating the action of endogenously released Ucn1 with an Ucn1 
depleting antibody or with the pan CRF receptor antagonist, α-helical-CRF, led to significant cell death in C-20/
A4 cells10. Here, we used the selective CRF-R1 and R2 antagonists CP-154526, and astressin 2B, respectively, to 
Figure 1. Analysis of the Ucn1 system in AC. RT-PCR analysis of transcripts derived from AC revealed the 
presence of Ucn1, CRF-R1 and CRF-R2 at the mRNA level. Predicted amplicon sizes and PCR conditions are 
summarised in Supplementary Table S1.
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determine the receptor subtype responsible for this pro-survival effect of Ucn1 and found that CP-154526 caused 
a dose dependant increase in antagonist-induced cell death in both C-20/A4 cells and AC. However, astressin 
2B had no effect, demonstrating that CRF-R1 is the receptor responsible for transducing the pro-survival effect 
of Ucn1. Furthermore, when CP-154526 and astressin 2B were given together, no further increase in cell death 
was detected; possibly suggesting that CRF-R1 is the sole receptor responsible for this effect (Fig. 2). The role of 
CRF-R2 in these cells is as yet unknown.
Blockade of CRF-R1 caused apoptotic cell death as determined by Annexin V/PI staining and by using 
Western immunoblotting along with antagonist-induced cell death, we were able to demonstrate that CP-154526 
but not astressin 2B caused an upregulation of p53 protein levels. As a transcription factor, p53 trans-activates a 
series of target genes known to inhibit cell proliferation and induce apoptosis in response to various stressors41. 
p53 expression and apoptosis also correlate with cartilage destruction in OA5, 42. Furthermore, in our system 
CP-154526 also caused cleavage of both the initiator caspase 9 and the effector caspase 3, but not caspase 8, 
suggesting that in the absence of Ucn1, this antagonist induced cell death is working through the intrinsic or 
Figure 2. Response of C-20/A4 cells and AC to Ucn1 blockade. Cells were treated for 8 h with CP-154526, 
astressin 2B or in combination at indicated concentrations. (A) The effects on morphology of incubating C-20/
A4 cells and AC with CP-154526 and/or astressin 2B (1–50 μM) was assessed using phase contrast microscopy. 
(B) Dose dependant effects of CP-154526 and/or astressin 2B on C-20/A4 cells. (C) AC cell death as determined 
by Annexin V/PI staining and flow cytometry. n = 3, error bars = SD *p < 0.05 and **p < 0.005 compared with 
untreated control cells.
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mitochondrial apoptotic pathway (Fig. 3). Significantly, Ucn1 has also been demonstrated to prevent mitochon-
drial damage caused by pro-apoptotic stimuli in other cells43.
Ucn1 is intimately linked to the regulation of ion channels in many cell types and under different physiolog-
ical conditions24–28. Therefore, in this study, we hypothesised that Ucn1 signalling may also exert its protective 
effect via blockade of a cation channel and prevent excessive Ca2+ overload. In chondrocytes several studies have 
demonstrated that excessive Ca2+ overload leads to cell death44, 45. To investigate this hypothesis we used the Ca2+ 
indicator dye Fluo-4 AM and demonstrated an increase in intracellular Ca2+ in the presence of CP-154526 in 
both our chondrocyte cell line and AC respectively (Fig. 4A–E). Furthermore, this increase in intracellular Ca2+ 
was associated with an increase in cell death and the ability of Gd3+ to both prevent this increase in Ca2+ and cell 
death suggest a role for a non-selective cation channel in CP-154526 induced cell death (Fig. 4C,F). The detection 
of an increase in intracellular Ca2+ influx implicates a loss of calcium homeostasis in CP-154526 induced cell 
death. In agreement with this is the finding that the Ucn1 homologue CRF has been shown to protect neurons 
against insults relevant to Alzheimer’s disease by stabilising neuronal Ca2+ homeostasis. In addition, Ucn1 had 
also been demonstrated to protect neurons against excitotoxic insults46–48.
We extended our investigation further in C-20/A4 cells to determine the identity of this Ucn1 regulated, 
Gd3+ sensitive cell death and Ca2+ influx. We used a panel of siRNAs directed towards 16 candidate ion chan-
nels commonly found in and exerting known functions on chondrocytes. Following transfection, the effect of 
CP-154526 on C-20/A4 cell death was assessed by both AnnexinV/PI staining and LDH release (Supplementary 
Figure S1). We found that only those cells with attenuated levels of Piezo1 and Piezo2 protein were protected from 
CP-154526 induced cell death, suggesting a role for these ion channels in cell death and Ca2+ overload, as both 
channels are known to gate calcium under conditions of compressive load34. We performed repeat experiments 
using siRNA for Piezo1 and Piezo2 and found that only Piezo1 knock down gave significant protection from 
both CP-154526 induced cell death and CP-154526 induced Ca2+ overload (Fig. 5). This data strongly implicates 
Piezo1 as the channel responsible for the cell death seen when Ucn1 is prevented from activating CRF-R1. As 
referred to in our introduction, C-20/A4 cells are acknowledged to be a good model for primary chondrocytes39. 
In this study, the results obtained from C-20/A4 cells were consistently confirmed in primary chondrocytes. 
Therefore, although our siRNA experiments were performed on C-20/A4 cells, we feel confident that Piezo1 is 
the ion channel involved in Ucn1 chondroprotection. In agreement with our study, Piezo1 was found to induce 
apoptosis of human chondrocytes following a compressive load which involved the MAPK/ERK1/2 signalling 
pathway49. Furthermore, Piezo1 can sense both mechanical crowding and stretch, suggesting it may act as a 
homeostatic sensor to control cell number, triggering extrusion and apoptosis in crowded regions and cell divi-
sion in sparse regions50.
We went on to determine the signalling pathway involved in this Piezo1 dependant cell death. CRF receptors 
have been reported to be highly promiscuous with regard to their second messenger signalling pathways and can 
bind to multiple G-protein isoforms depending on the cell type and circumstance. Upon agonist activation, CRF 
receptors predominantly activate either Gαs or Gαq resulting in the generation of cAMP via adenylate cyclase, 
or IP3 and diacylglycerol via PLC51–53. We found that the activation of adenylate cyclase by forskolin but not the 
activation of PLC with m-3M3FBS, was able to rescue chondrocytes from antagonist-induced cell death, demon-
strating that CRF-R1, when bound to Ucn1 in chondrocytes, is coupled to Gαs and is responsible for the genera-
tion of cAMP, and therefore the regulation of protein kinase A (PKA) activity (Fig. 6A). Recently, Piezo2 current 
amplitude was demonstrated to be increased, and inactivation was slowed, by bradykinin 2 receptor (BDKRB2) 
Figure 3. Western immunoblot analysis of C-20/A4 cells treated with CP-154526 and/or astressin 2B. Protein 
extracts were electrophoresed and probed with the indicated primary antibodies. Expected molecular sizes 
are indicated. p53 was upregulated in response to CP-154526 (50 μM) but not astressin 2B (50 μM). Cleaved 
caspases 3 and 9 were detected in the presence of CP-154526 but not in the presence of astressin 2B or non-
treated cells. The images have been cropped but gels were run under the same experimental conditions. 
Representative images of 3 independent experiments.
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Figure 4. Antagonist induced calcium influx is inhibited by the non-selective cation channel blocker 
gadolinium. (A) C-20/A4 cells were treated at indicated time points CP-154526 (50 μM) alone or in the presence 
of Gd3+ (100 µM). Intracellular Ca2+ levels were visualised by fluorescent microscopy and Fluo-4 AM staining. 
Representative images of 3 independent experiments are shown. (B) Fluo-4 signal quantification using ImageJ 
software and graphical representation of Fluo-4 staining intensity for C-20/A4 cells treated with CP-154526 
(50 μM) alone or in the presence of Gd3+ (100 µM). Mean fluorescent intensities are reported, n = 3, error 
bars = SD, *p < 0.05. (C) The ability of Gd3+ treatment to protect C-20/A4 cells against CP-154526 induced cell 
death was determined by Annexin V/PI staining and flow cytometry, n = 3, error bars = SD, *p < 0.05. (D) AC 
cells were treated with CP-154526 (50 μM) alone or in the presence of Gd3+ (100 µM). Intracellular Ca2+ levels 
were visualised by fluorescent microscopy and Fluo-4 AM staining. Representative images of 3 independent 
experiments are shown. (E) Fluo-4 signal was quantified using ImageJ software and graphical representation 
of Fluo-4 staining intensity for AC cells treated with CP-154526 alone or in the presence of Gd3+ (100 µM). 
Mean fluorescent intensities are reported, n = 3, error bars = SD, *p < 0.05. (F) The ability of Gd3+ treatment to 
protect primary AC cells against CP-154526 induced cell death was determined by Annexin V/PI staining and 
flow cytometry, n = 3, error bars = SD, *p < 0.05.
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Figure 5. Inhibition of mechanosensitive Piezo1 can protect C-20/A4 cells from CP-154526 induced apoptosis 
and calcium influx (A). C-20/A4 cells were transfected with siRNA (20 nM) against Piezo1, Piezo2 and a 
Scrambled control in the presence of HiPerFect, and cultured for 72 h before treatment with CP-154526 
(50 µM). Phase contrast images were collected at 5 h post-CP treatment to record changes to cell morphology. 
Images of the centre of each well are presented. Representative images of 3 independent experiments are shown. 
(B) Cell death in transfected and control cells was assessed 5 h post CP treatment by AnnexinV/PI staining 
and flow cytometry, n = 5, error bars = SEM, *p < 0.05. (C) Cell death measured by LDH (absorbance at 
490 nm) release into the media. n = 5, error bars = SEM, *p < 0.05. (D) Intracellular Ca2+ levels were visualised 
in control and transfected C-20/A4 cells by fluorescent microscopy following staining with Fluo-4 AM and 
Hoescht-33342. Cells were treated for 3 h with CP-154526 (50 µM). Representative images of 3 independent 
experiments are shown. (E) Fluo-4 AM intensity was quantified on ImageJ software to assess calcium influx in 
all cells. Mean fluorescent intensities are reported, n = 3, error bars = SEM, *p < 0.05.
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activation in heterologous expression systems. This G-protein coupled receptor produced this effect by activat-
ing both PKA and PKC, whereas the effect was abolished by PKA and PKC inhibitors54. Although the effect of 
BDKRB2 agonism was to activate a Piezo channel rather than to produce an inhibitory effect, (as seen with Ucn1), 
clearly there is a role for G-protein coupled receptor activation in the regulation of Piezo channels. Indeed inhi-
bition of Piezo1 and Piezo2 was found to be caused by depletion of phosphatidylinositol 4,5-bisphosphate and its 
precursor PI(4)P from the plasma membrane by Ca2+ - induced phospholipase Cδ activation55. These findings 
imply a role for membrane bound lipid factors in channel regulation. Our results clearly demonstrate, however, 
that adenylate cyclase, rather than PLC, is involved in Piezo1 regulation by Ucn1. Several known endogenous 
modulators of non-selective cation channels include lipid based ligands derived from enzymatic catabolism of 
arachidonic acid (AA) by cytochrome P450 epoxygenase56–58. AA itself is derived from the degradation of mem-
brane phospholipids usually by PLC. An alternative route for the derivation of lipid modulators during antagonist 
induced cell death is the generation of AA by PLA259. Indeed, using the PLA2 inhibitor OBAA, we were able 
to demonstrate that antagonist induced cell death involved activation of PLA2, as its inhibition was protective 
when CP-154526 was applied to chondrocytes (Fig. 6B). This implies that activation of PLA2 is required for 
CP-154526 induced cell death and that when Ucn1 is present, PLA2 is inactive, thereby preventing the generation 
of endogenous lipid based channel openers. Significantly, Ucn1 has been demonstrated to both down-regulate 
calcium-independent PLA2 (iPLA2)60 and regulate its activity61 in other systems during cell stress. Of note, an 
iPLA2 type enzyme producing AA and lysophospholipids from the plasma membrane, has been demonstrated to 
modulate a store operated channel activity by regulating iPLA2 kinetics through cAMP/PKA dependant rather 
than PLC dependant mechanisms62. Furthermore, multiple isoforms of PLA2 have been revealed to participate in 
inflammatory processes in OA63, further implicating this pathway in the progression of OA.
Here, we have dissected the signalling pathway from the CRF receptor to the regulation of Piezo1. This involves 
both cAMP and PLA2, and demonstrates that Ucn1 is crucial for indirect gating of this channel. Importantly, 
removal of the CRF-R1 block, causes persistent and excessive opening of Piezo1 resulting in Ca2+ overload and 
subsequent cell death (Fig. 7). Therefore, the bioavailability and concentration of Ucn1 and factors affecting 
this would be of crucial importance to maintain correct calcium homeostasis in chondrocytes. This would be of 
immense interest in understanding and exploiting chondrocyte cell fate in health and disease. Our study is the 
first to demonstrate a role for Ucn1 in the regulation of a mechanosensitive channel, Piezo1. Therefore, the label 
‘mechanosensitive channel’ belies its more complex regulatory nature, in that as well as being gated by mechanical 
force, Piezo1 in chondrocytes is also regulated by intracellular signals generated by a G-protein coupled receptor. 
We have previously found that Ucn1 can protect chondrocytes from both pro-apoptotic factors associated with 
OA and acute impact injury (Unpublished observations). Ucn1, therefore, may represent a link between cellular 
derived factors and injurious factors both capable of the production of OA through different pathways. Much 
work is still required to fully elucidate this novel chondroprotective pathway. However, once found, it will open 
Figure 6. Identification of downstream signalling associated with CRF-R1. (A) The effect of the adenylate 
cyclase activator forskolin (0.1 μM) and the PLC activator m3M3FBS (0.1 μM) on CP-154526 (50 μM) induced 
C-20/A4 cell death as determined by Annexin V/PI staining and flow cytometry. n = 3, error bars = SD 
**p < 0.005 compared with control. (B) The effect of the PLA2 inhibitor OBAA (0.1 μM) on CP-154526 (50 μM) 
induced C-20/A4 cell death as determined by Annexin V/PI staining and flow cytometry. n = 3, error bars = SD 
**p < 0.005 compared with control (untreated).
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 5147  | DOI:10.1038/s41598-017-04367-4
up new approaches for the development of novel treatments that could prevent or modulate the progression of 
OA, rather than just addressing the symptoms of the disease.
Materials and Methods
Cell culture. The C-20/A4 human chondrocyte cell line was cultured in a medium consisting of Dulbecco’s 
modified Eagle’s medium (Invitrogen, UK), supplemented with 10% (v/v) foetal calf serum (FCS, UK)1% (v/v) 
and 1% (v/v) penicillin/streptomycin (Invitrogen, UK) at 37 °C, 5% CO2. Cells were passaged by treatment with 
Ca2+ and Mg2+-free phosphate-buffered saline, pre-warmed to 37 °C and used as required. Following passage, the 
chondrocyte cell suspension (1 × 106 cells/ml) was transferred to six-well tissue culture plates and incubated for 
24–48 h in the above medium to allow cells to reach ∼80% confluency. The cells were then ‘serum starved’ for 24 h 
by replacing the normal, 10% FCS growth medium with medium containing 1% FCS (all other components were 
unchanged). Cells were then treated as indicated in specific experiments.
Primary human chondrocytes isolation and culture. These methods and experimental protocols were 
carried out in accordance with the approved guidelines as approved by the National Research Ethics service and 
the University of Manchester ethics committee number 10/H1013/27. Written informed consent was obtained 
from all patients. Femoral heads were collected from patients undergoing total hip or knee replacement sur-
gery and stored in serum-free DMEM with antibiotics/antimycotics until processed (Supplementary Table S1). 
Femoral head cartilage was shaved off using a scalpel and incubated overnight with agitation in serum-free 
DMEM containing an enzymatic cocktail of 0.25% collagenase type II (Life Technologies) and 0.1% hyaluroni-
dase in serum-free medium (Sigma) to release the AC. The next day the solution was centrifuged and the pelleted 
ACs resuspended and plated in DMEM supplemented with 10% foetal calf serum (FCS) at a density of approx-
imately 5,000–6,000 per cm2. Cells were then incubated for 24–48 h in the above medium to allow cells to reach 
∼80% confluency. The cells were then ‘serum starved’ for 24 h by replacing the normal, 10% FCS growth medium 
with medium containing 1% FCS (all other components unchanged). Cells were then treated as indicated in 
specific experiments.
RNA isolation and RT-PCR. Total RNA was isolated using Qiagen RNeasy RNA isolation kit (Qiagen) 
and Total RNA was subjected to on-column RNase-free DNase digestion. RNA purity and concentration were 
determined spectrophotometrically at 260 and 280 nm using a NanoDrop 2000c spectrophotometer (Thermo 
Scientific). RNA integrity was verified by 1% agarose gel (containing GelRedTM) electrophoresis. The gel was 
visualised on a UV transilluminator. cDNA was synthesised from 2 µg of RNA using oligo dT primer in a 20 μl 
first-strand cDNA synthesis reactions containing 18 units of AMV reverse transcriptase (Promega). The reaction 
was terminated by incubation at 94 °C for 3 minutes and then stored at −20 °C until use. Amplification was per-
formed with 3 μl of cDNA for GAPDH, Ucn1, CRF-R1 and CRF-R2 under conditions described in Supplementary 
Table S2. Amplified PCR products were analysed on agarose gels.
Pharmacological treatment of cells. Six-well plate cultures of either the C-20/A4 cell line or AC 
were treated for 8 h with individual or combination treatments of: the CRF-R1 specific antagonist CP-154526 
(1–50 μM; Tocris), the CRF-R2 specific antagonist astressin 2B (1–50 μM; Tocris), the non-selective cation chan-
nel blocker Gd3+ (100 μM; Tocris), the adenylate cyclase activator forskolin (0.1 μM; Tocris), the PLC activator 
m3M3FBS (0.1 μM; Tocris), or the PLA2 inhibitor OBAA (0.1 μM; Tocris). Cells were then assayed for cell death 
or photographed using an Olympus IX73 phase contrast microscope and camera.
Figure 7. Schematic diagram depicting the mechanisms by which Ucn1 promotes chondrocyte cell survival. 
(A) During chondrocyte cell survival, Ucn1 is bound to CRF-R1 in an autocrine/paracrine fashion. This causes 
recruitment of Gαs which activates adenylate cyclase, producing elevated levels of cAMP. cAMP then activates 
PKA which causes the inactivation of PLA2 reducing the breakdown of membrane phospholipids, thereby 
reducing the production of ion channel openers. This results in Piezo1 remaining in a closed conformation, 
preventing Ca2+ overload. (B) However, if the agonist effect of Ucn1 for CRF-R1 is removed, in this case by the 
selective antagonist CP-154526, Gαs is not recruited by CRF-R1 and therefore adenylate cyclase is not activated 
resulting in a reduction in cAMP levels. This then causes the inactivation of PKA which results in the removal of 
its block on PLA2 which therefore becomes activated, increasing the generation of potential lipid openers of the 
Piezo1 channel. If this situation is maintained, the cell experiences a Ca2+ overload and ultimately cell death.
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Transient transfection of C-20/A4 cells. A panel of siRNA’s against candidate ion channels and con-
trols was purchased from Dharmacon (GE Dharmacon) each siRNA was a pool of 4 sequences (Supplementary 
Table S3). All siRNA was reconstituted to 20 µM stock concentration in RNase-free water. C-20/A4 cells were 
plated at a density of 250,000 cells/well of a 6 well plate in 10% FCS media as described above, and incubated at 
37 °C and 5% CO2 for 30 minutes. Reconstituted siRNA was diluted to 20 nM working concentration in 200 μl 
of Opti-MEM (Gibco). 12 µl of HiPerFect (Qiagen) was added to the siRNA and Opti-MEM and incubated 
for 15 minutes at room temperature. Following incubation, siRNA solution was added to cells in a dropwise 
manner and incubated in normal culture conditions for 48 h. 12 h before collection, media was changed on all 
wells and replaced with 1% FCS media. siPiezo1 and siPiezo2 of the same pooled sequences was purchased from 
Dharmacon for further experiments. C-20/A4 cells were transfected with 20 nM siRNA against Piezo1, Piezo2 
and a Scrambled control in the presence of HiPerFect, and cultured for 72 h before treatment with CP-154526 
(50 µM). Phase contrast images were collected at 5 h post-CP treatment.
Detection of cell death- flow cytometry and Lactate dehydrogenase (LDH). Cell death was 
detected using the Annexin V-FITC Apoptosis Detection Kit I (BD Bioscience) as per the manufacturer’s instruc-
tions. Cells were harvested by trypsinisation, washed in PBS and resuspended in binding buffer containing 5 µl of 
annexin V-FITC and 5 µl PI staining solution and incubated for 15 minutes at room temperature in the dark. Cells 
were then analysed on a BD Accuri C6TM flow cytometer. Data was analysed using BD Accuri C6TM software.
LDH assays were conducted on media collected at 5 h post-treatment with CP-154526 (Pierce™ LDH 
Cytotoxicity Assay Kit, Thermo Fisher Scientific, catalogue number 88954). Media was thoroughly agitated and 
50 µl added to wells of a 96-well plate in duplicate. 50 µl reaction buffer was added to each sample, and mixed by 
pipetting 5 times. The plate was then incubated in the dark at room temperature for 30 minutes. Reaction was 
stopped with 50 µl stop solution provided with the kit. Absorbance was recorded at both 490 nm and 680 nm on 
SpectraMax M5 plate reader (Molecular Devices, CA, USA). Positive controls provided with the kit and negative 
controls in the form of culture media alone were conducted with every experiment. Readings were adjusted for 
background fluorescence by subtracting the value recorded at 680 nm from that recorded at 490 nm for each 
sample. Final values presented are an average of the duplicated readings with background absorbance reading 
subtracted.
Immunoblotting. Cells were harvested using trypsin digestion and lysed using RIPA buffer with protease 
inhibitor cocktail (Sigma). Total protein was quantified using BCA protein assay kit (Pierce) and equal quantities 
of denatured protein were subjected to electrophoresis on SDS-polyacrylamide gels, blotted onto Immobilon-FC 
transfer membrane (Sigma) and probed with the following specific primary antibodies; anti-p53 (Cell Signalling 
Technology, 9282), anti-cleaved caspase 3 (EMD Millipore, AB3623), anti-cleaved caspase 9 (EMD Millipore, 
AB3629), and anti-GAPDH (Abcam, ab8245). Blots were washed and probed with the following appropriate 
secondary antibodies; goat anti-rabbit IgG IRDye 800CW (IRDye antibodies, 926–32211), goat anti-mouse IgG 
IRDye 800CW (IRDye Antibodies, 926–32210) or goat anti-rabbit IgG IRDye 680LT (IRDye Antibodies, 926–
68021). The signal was visualised using a LICOR Odyssey imaging system.
Analysis of intracellular Ca2+ levels. Intracellular Ca2+ levels were visualised using fluorescent micros-
copy and Fluo-4 AM permeant dye (Thermo Fisher Scientific). After incubation with Gd3+ (100 μM) and 
CP-154526 (50 μM), cells were incubated within media containing 1 µM Fluo-4 AM and 5 μg/ml Hoechst 33342 
for 30 minutes at 37 °C before being washed twice with HEPES buffered saline solution and imaged using an 
Olympus IX73 fluorescent microscope.
Statistical analysis. Data values from the figures are expressed as mean ± standard deviation of the mean. 
All data were subjected to a one way ANOVA followed by a Tukey HSD test where appropriate. Probabilities of 
p < 0.05 were considered statistically significant. Statistical analysis was performed using GraphPad Prism.
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